LIVIVO - Search results -

Search results

Result 1 - 10 of total 13

Search options

Article ; Online: Coronary vein graft disease: pathogenesis and prevention.

Parang, Pirouz / Arora, Rohit

2009 Volume 25, Issue 2, Page(s) e57–62

Abstract: ... of saphenous vein grafts fail within 10 to 15 years of surgery and that graft failure is associated with worse ... of vein graft patency. Various gene therapies can prevent intimal hyperplasia in animal models, but human ... thrombosis and graft failure. As in native coronaries, intensive lipid lowering can attenuate the process ...

Abstract	Not long after coronary artery bypass grafting surgery was described, several reports presented follow-up angiographic data on large cohorts of patients, demonstrating that approximately one-half of saphenous vein grafts fail within 10 to 15 years of surgery and that graft failure is associated with worse clinical outcomes. Three processes are responsible for vein graft failure. Thrombosis, intimal hyperplasia and accelerated atherosclerosis contribute to graft failure in the acute, subacute and late postoperative periods, respectively. Studies have shown that perioperative antiplatelet therapy can reduce early thrombosis and graft failure. As in native coronaries, intensive lipid lowering can attenuate the process of atherosclerosis in vein grafts. Intimal hyperplasia in the vein graft is thought to be an adaptation of the vein to higher pressures in the arterial circulation. This process is further promoted by the loss of inhibition from the endothelial layer, which is injured during surgery. A new 'no-touch' technique for harvesting grafts may be effective in preventing disruption to the endothelial layer, and subsequent intimal hyperplasia and graft loss. Off-pump surgery and endoscopic vein harvesting, which are known to reduce surgical morbidity, have been shown to be no worse than on-pump surgery and open vein harvesting, respectively, in terms of vein graft patency. Various gene therapies can prevent intimal hyperplasia in animal models, but human data obtained so far have been disappointing. Placing an external stent around a vein graft may reduce tangential wall stress and subsequent intimal hyperplasia.
MeSH term(s)	Anticholesteremic Agents/therapeutic use ; Coronary Artery Bypass ; Coronary Artery Bypass, Off-Pump ; Coronary Vessels/pathology ; Coronary Vessels/physiopathology ; Genetic Therapy ; Graft Occlusion, Vascular/pathology ; Graft Occlusion, Vascular/physiopathology ; Graft Occlusion, Vascular/prevention & control ; Graft Survival ; Humans ; Risk Factors ; Stents ; Veins/pathology ; Veins/physiopathology
Chemical Substances	Anticholesteremic Agents
Language	English
Publishing date	2009-02-13
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	632813-1
ISSN	1916-7075 ; 0828-282X
ISSN (online)	1916-7075
ISSN	0828-282X
DOI	10.1016/s0828-282x(09)70486-6
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 2150: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article: Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention.

Motwani, J G / Topol, E J

Circulation

1998 Volume 97, Issue 9, Page(s) 916–931

Abstract: ... when transposed into the coronary arterial circulation. A multifaceted strategy aimed at prevention of vein graft ... nitric oxide donor administration, which target vein graft disease at an early and fundamental level. At present ... to vein graft atherosclerosis are broadly similar to those recognized for native coronary disease ...

Abstract	Aortocoronary saphenous vein graft disease, with its increasing clinical sequelae, presents an important and unresolved dilemma in cardiological practice. During the 1st month after bypass surgery, vein graft attrition results from thrombotic occlusion, while later the dominant process is atherosclerotic obstruction occurring on a foundation of neointimal hyperplasia. Although the risk factors predisposing to vein graft atherosclerosis are broadly similar to those recognized for native coronary disease, the pathogenic effects of these risk factors are amplified by inherent deficiencies of the vein as a conduit when transposed into the coronary arterial circulation. A multifaceted strategy aimed at prevention of vein graft disease is emerging, elements of which include: continued improvements in surgical technique; more effective antiplatelet drugs; increasingly intensive risk factor modification, in particular early and aggressive lipid-lowering drug therapy; and a number of evolving therapies, such as gene transfer and nitric oxide donor administration, which target vein graft disease at an early and fundamental level. At present, a key measure is to circumvent the problem of vein graft disease by preferential selection of arterial conduits, in particular the internal mammary arteries, for coronary bypass surgery whenever possible.
MeSH term(s)	Arteriosclerosis/etiology ; Arteriosclerosis/prevention & control ; Coronary Artery Bypass ; Humans ; Hyperplasia/etiology ; Hyperplasia/prevention & control ; Hypolipidemic Agents/therapeutic use ; Platelet Aggregation Inhibitors/therapeutic use ; Risk Factors ; Saphenous Vein/pathology ; Saphenous Vein/transplantation ; Smoking Cessation ; Thrombosis/etiology ; Thrombosis/prevention & control
Chemical Substances	Hypolipidemic Agents ; Platelet Aggregation Inhibitors
Language	English
Publishing date	1998-03-10
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	80099-5
ISSN	1524-4539 ; 0009-7322 ; 0069-4193 ; 0065-8499
ISSN (online)	1524-4539
ISSN	0009-7322 ; 0069-4193 ; 0065-8499
DOI	10.1161/01.cir.97.9.916
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ui IV Zs.60: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Revascularisation of type 2 diabetics with coronary artery disease: Insights and therapeutic targeting of O-GlcNAcylation.

Bolanle, Israel O / Riches-Suman, Kirsten / Loubani, Mahmoud / Williamson, Ritchie / Palmer, Timothy M

Nutrition, metabolism, and cardiovascular diseases : NMCD

2021 Volume 31, Issue 5, Page(s) 1349–1356

Abstract: ... initiates vein graft failure. This review gives novel insights into these cellular and molecular mechanisms ... and identifies potential therapeutic targets for development of new medicines to improve vein graft ... Aim: Coronary artery bypass graft (CABG) using autologous saphenous vein continues to be a gold ...

Abstract	Aim: Coronary artery bypass graft (CABG) using autologous saphenous vein continues to be a gold standard procedure to restore the supply of oxygen-rich blood to the heart muscles in coronary artery disease (CAD) patients with or without type 2 diabetes mellitus (T2DM). However, CAD patients with T2DM are at higher risk of graft failure. While failure rates have been reduced through improvements in procedure-related factors, much less is known about the molecular and cellular mechanisms by which T2DM initiates vein graft failure. This review gives novel insights into these cellular and molecular mechanisms and identifies potential therapeutic targets for development of new medicines to improve vein graft patency. Data synthesis: One important cellular process that has been implicated in the pathogenesis of T2DM is protein O-GlcNAcylation, a dynamic, reversible post-translational modification of serine and threonine residues on target proteins that is controlled by two enzymes: O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). Protein O-GlcNAcylation impacts a range of cellular processes, including trafficking, metabolism, inflammation and cytoskeletal organisation. Altered O-GlcNAcylation homeostasis have, therefore, been linked to a range of human pathologies with a metabolic component, including T2DM. Conclusion: We propose that protein O-GlcNAcylation alters vascular smooth muscle and endothelial cell function through modification of specific protein targets which contribute to the vascular re-modelling responsible for saphenous vein graft failure in T2DM.
MeSH term(s)	Animals ; Biomarkers/blood ; Blood Glucose/metabolism ; Coronary Artery Bypass/adverse effects ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/etiology ; Coronary Artery Disease/metabolism ; Coronary Artery Disease/surgery ; Diabetes Mellitus, Type 2/blood ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/diagnosis ; Diabetes Mellitus, Type 2/drug therapy ; Glycosylation ; Graft Occlusion, Vascular/etiology ; Graft Occlusion, Vascular/metabolism ; Graft Occlusion, Vascular/pathology ; Graft Occlusion, Vascular/prevention & control ; Humans ; Protein Processing, Post-Translational/drug effects ; Risk Assessment ; Risk Factors ; Saphenous Vein/metabolism ; Saphenous Vein/pathology ; Saphenous Vein/transplantation ; Treatment Failure ; Vascular Remodeling
Chemical Substances	Biomarkers ; Blood Glucose
Language	English
Publishing date	2021-02-02
Publishing country	Netherlands
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	1067704-5
ISSN	1590-3729 ; 0939-4753
ISSN (online)	1590-3729
ISSN	0939-4753
DOI	10.1016/j.numecd.2021.01.017
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 3149: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: A five-parameter score for predicting saphenous vein graft degenerative and/or occlusive disease in recurring ischemic symptoms after one year post coronary artery bypass grafting.

Li, Xiao-Wei / Cui, Zhuang / Xiao, Jian-Yong / Gao, Ming-Dong / Zhang, Mei / Zhang, Wen-Juan / Tian, Feng-Shi / Song, Yu / Liu, Ying-Wu / Yao, Zhu-Hua / Ma, Jun / Liu, Yin / Gao, Jing

Perfusion

2022 Volume 38, Issue 4, Page(s) 843–852

Abstract: ... is increasing in recent years. How to prevent and treat saphenous vein graft disease (SVGD ... symptomatic ⩾50% stenosis in at least one Saphenous vein graft]) has been a clinical challenge to date ... Background: The recurrence rate of ischemic symptoms after coronary artery bypass grafting (CABG ...

Abstract	Background: The recurrence rate of ischemic symptoms after coronary artery bypass grafting (CABG) is increasing in recent years. How to prevent and treat saphenous vein graft disease (SVGD [symptomatic ⩾50% stenosis in at least one Saphenous vein graft]) has been a clinical challenge to date. Different pathogenesis may exist in SVGD of different periods. There are currently few available scores for estimating the risk of SVGD after one year post CABG. Objective: We sought to develop and validate a simple predictive clinical risk score for SVGD with recurring ischemia after one year post CABG. Methods and results: This was a cross-sectional study and the results were validated using bootstrap resampling on a separate cohort. A nomogram and risk scoring system were developed based on retrospective data from a training cohort of 606 consecutive patients with recurring ischemia >1 year after CABG. Logistic regression model was used to find the predictive factors and to build a nomogram. To assess the generalization, models were validated using bootstrap resampling and an external cross-sectional study of 187 consecutive patients in four other hospitals. In multivariable analysis of the primary cohort, native lesion vessel number, SVG age, recurring ischemia type, very low-density lipoprotein level, and left ventricular end-diastolic diameter were independent predictors. A summary risk score was derived from nomogram, with a cut-off value of 15. In internal and external validation, the C-index was 0.86 and 0.82, indicating good discrimination. The calibration curve for probability of SVGD showed optimal agreement between actual observations and risk score prediction. Conclusion: A simple-to-use risk scoring system based on five easily variables was developed and validated to predict the risk of SVGD among patients who recurring ischemia after one year post CABG. This score may be useful for providing patients with individualized estimates of SVGD risk.
MeSH term(s)	Humans ; Saphenous Vein ; Retrospective Studies ; Cross-Sectional Studies ; Coronary Artery Bypass/adverse effects ; Ischemia ; Treatment Outcome ; Coronary Artery Disease ; Coronary Angiography ; Vascular Patency
Language	English
Publishing date	2022-05-18
Publishing country	England
Document type	Journal Article
ZDB-ID	645038-6
ISSN	1477-111X ; 0267-6591
ISSN (online)	1477-111X
ISSN	0267-6591
DOI	10.1177/02676591221090588
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 2424: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Management of Saphenous Vein Graft Disease in Patients with Prior Coronary Artery Bypass Surgery.

Dianati Maleki, Neda / Ehteshami Afshar, Arash / Parikh, Puja B

Current treatment options in cardiovascular medicine

2019 Volume 21, Issue 2, Page(s) 12

Abstract: ... on various aspects of prevention and management of SVG failure.: Recent findings: Application ... by thrombotic occlusion, intimal fibrosis, and accelerated atherosclerosis. Prevention of SVG failure is ... Purpose of review: In this review, we summarize the pathogenesis of saphenous venous graft (SVG ...

Abstract	Purpose of review: In this review, we summarize the pathogenesis of saphenous venous graft (SVG) failure in patients following coronary artery bypass graft (CABG) surgery. We also provide an update on various aspects of prevention and management of SVG failure. Recent findings: Application of perioperative measures and medical therapies to promote SVG patency is crucial to optimize clinical outcomes in patients following CABG. Percutaneous coronary intervention (PCI) of SVG disease is fraught with complications, with the highest risk being no-reflow and periprocedural myocardial infarction due to distal embolization of microemboli. Minimizing this risk with use of distal embolic protection when feasible and understanding the role of adjunctive pharmacotherapies is critical in reducing the risk of adverse cardiac events. The long-term patency of SVGs remains a contemporary challenge and is adversely affected by thrombotic occlusion, intimal fibrosis, and accelerated atherosclerosis. Prevention of SVG failure is multifactorial. Use of perioperative measures, medical therapies, and PCI techniques to promote SVG patency is vital to optimize outcomes in patients following CABG. Further prospective trials are needed to define the optimal medical and surgical therapy to maintain short- and long term SVG patency.
Language	English
Publishing date	2019-02-28
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2057337-6
ISSN	1534-3189 ; 1092-8464
ISSN (online)	1534-3189
ISSN	1092-8464
DOI	10.1007/s11936-019-0714-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5529: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Bone morphogenic protein-4: a potential novel target for preventing vein graft failure in coronary revascularization.

Hu, Jia / Zhao, Jing Janice

Medical hypotheses

2013 Volume 81, Issue 6, Page(s) 1025–1028

Abstract: ... agent has hitherto proven clinically effective in preventing short- and long-term vein graft failure ... inhibition could presumably serve as a novel strategy for preventing vein graft failure in coronary ... syndrome and chronic coronary stenotic disease refractory to pharmacological treatment. Despite rapid ...

Abstract	Coronary artery bypass surgery is an effective and durable therapy in both acute coronary syndrome and chronic coronary stenotic disease refractory to pharmacological treatment. Despite rapid development in operation-specific technologies and secondary prevention measures, the benefits of surgical revascularization are largely limited by inadequate patency of one of the most commonly used conduits, namely the autologous saphenous vein. However, apart from antiplatelet and lipid-lowering drugs, no other pharmacologic agent has hitherto proven clinically effective in preventing short- and long-term vein graft failure. Aiming at a large number of known biomolecules, multiple promising strategies failed to translate their beneficial effects observed in animal models into the clinical settings. Bone morphogenic protein-4 (BMP4), originally identified as a mediator in bone formation, has been recently demonstrated to participate in the process of arterial post-injury remodeling. Existing evidence has demonstrated that BMP4 is closely involved in the pathogenesis of thrombus formation, neointimal hyperplasia and superimposed atherosclerosis, all of which significantly contribute to arterial stenotic lesions. Although the post-injury responses inherent to arterial and venous vessel are unique, they share common elements and present with similar physiologic characteristics and clinical sequelae. Therefore, with regard to the multifaceted effects of BMP4 in regulating arterial wall remodeling, we hypothesize that BMP4 may play an important role in mediating the pathological responses of the venous wall to the arterial circulation. If our hypothesis is demonstrated correct, BMP4 inhibition could presumably serve as a novel strategy for preventing vein graft failure in coronary revascularization.
MeSH term(s)	Bone Morphogenetic Protein 4/antagonists & inhibitors ; Bone Morphogenetic Protein 4/metabolism ; Graft Occlusion, Vascular/drug therapy ; Graft Occlusion, Vascular/metabolism ; Graft Occlusion, Vascular/prevention & control ; Humans ; Models, Biological ; Myocardial Revascularization/adverse effects ; Myocardial Revascularization/methods ; Saphenous Vein/pathology ; Saphenous Vein/transplantation
Chemical Substances	BMP4 protein, human ; Bone Morphogenetic Protein 4
Language	English
Publishing date	2013-12
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	193145-3
ISSN	1532-2777 ; 0306-9877
ISSN (online)	1532-2777
ISSN	0306-9877
DOI	10.1016/j.mehy.2013.09.023
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1132: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Saphenous vein graft failure after coronary artery bypass surgery: pathophysiology, management, and future directions.

Harskamp, Ralf E / Lopes, Renato D / Baisden, Clinton E / de Winter, Robbert J / Alexander, John H

Annals of surgery

2013 Volume 257, Issue 5, Page(s) 824–833

Abstract: ... that may improve vein graft patency.: Background: VGF and progression of native coronary artery disease limit ... Objective: To review our current understanding of the epidemiology and pathogenesis of vein graft ... coronary artery bypass graft surgery. New developments in VGF prevention such as gene therapy, external graft support, fully ...

Abstract	Objective: To review our current understanding of the epidemiology and pathogenesis of vein graft failure (VGF), give an overview of current preventive and interventional measures, and explore strategies that may improve vein graft patency. Background: VGF and progression of native coronary artery disease limit the long-term efficacy of coronary artery bypass graft surgery. Methods: We reviewed the published literature on the pathophysiology, prevention, and/or treatment of VGF by searching the MEDLINE (January 1, 1966-January 1, 2012), EMBASE (January 1, 1980-January 1, 2012), and Cochrane (January 1, 1995-January 1, 2012) databases. In addition, we reviewed references from the selected articles for studies not identified in the initial search. Basic science and clinical studies were included; non-English language publications were excluded. Results: Acute thrombosis, neointimal hyperplasia, and accelerated atherosclerosis are the 3 mechanisms that lead to VGF. Preventive measures include matching and quality assessment of conduit and target vessel, lipid-lowering drugs, antithrombotic therapy, and cessation of smoking. Treatment of VGF includes medical therapy, percutaneous intervention, and redo coronary artery bypass graft surgery. In patients undergoing graft intervention, the use of drug-eluting stents, antiplatelet agents, and embolic protection devices may improve clinical outcomes. Conclusions: Despite advances in management, VGF remains one of the leading causes of poor in-hospital and long-term outcomes after coronary artery bypass graft surgery. New developments in VGF prevention such as gene therapy, external graft support, fully tissue-engineered grafts, hybrid grafts, and synthetic conduits are promising but unproven. Future efforts to reduce VGF require a multidisciplinary approach with a primary focus on prevention.
MeSH term(s)	Coronary Artery Bypass/methods ; Coronary Artery Disease/surgery ; Graft Occlusion, Vascular/epidemiology ; Graft Occlusion, Vascular/etiology ; Graft Occlusion, Vascular/physiopathology ; Graft Occlusion, Vascular/therapy ; Humans ; Percutaneous Coronary Intervention ; Reoperation ; Risk Factors ; Risk Reduction Behavior ; Saphenous Vein/physiopathology ; Saphenous Vein/transplantation ; Stents ; Treatment Failure
Language	English
Publishing date	2013-05
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	340-2
ISSN	1528-1140 ; 0003-4932
ISSN (online)	1528-1140
ISSN	0003-4932
DOI	10.1097/SLA.0b013e318288c38d
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uk I Zs.35/1: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: [Syndrome differentiation patterns for peri-operative coronary heart disease patients of coronary artery bypass graft].

Wu, H L / Ruan, X M / Zhang, M Z

Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine

2001 Volume 21, Issue 6, Page(s) 409–411

Abstract: Objective: To explore the patterns of Syndrome Differentiation of coronary artery bypass graft ... CABG) on the peri-operative coronary heart disease (CHD) patients.: Methods: One week after ... with Stasis in blood, suggesting that Qi-deficiency, phlegm and stasis are the basic pathogenesis in patients ...

Abstract	Objective: To explore the patterns of Syndrome Differentiation of coronary artery bypass graft (CABG) on the peri-operative coronary heart disease (CHD) patients. Methods: One week after operation, thirty-seven CHD patients, who received CABG of internal mammary artery or great saphenous vein under conventional general anesthesia with low or middle temperature extracorporeal circulation were differentiated as various syndromes, the pre- and post-operational ECG, color Doppler echocardiography as well as during and after operation. The hemodynamic parameters were monitored. Results: In the CHD patients, 64.9% were differentiated as Qi-Yin deficiency, 67.6% were complicated with Phlegm Syndrome and 62.2% with Stasis in blood, suggesting that Qi-deficiency, phlegm and stasis are the basic pathogenesis in patients after CABG. Moreover, the peri-operative Syndrome was correlated with the condition of coronary arterial lesions, heart and lung functions before operation, and the time for extracorporeal circulation during the operation. Conclusion: TCM Syndrome Differentiation conducting in peri-operative stage might be useful to explore the patterns of Syndrome alteration which provided a basis for preventing peri-operational complication and elevating success rate of operation.
MeSH term(s)	Adult ; Aged ; Coronary Artery Bypass ; Coronary Disease/drug therapy ; Coronary Disease/surgery ; Diagnosis, Differential ; Female ; Humans ; Intraoperative Period ; Male ; Medicine, Chinese Traditional ; Middle Aged ; Qi
Language	Chinese
Publishing date	2001-06
Publishing country	China
Document type	English Abstract ; Journal Article
ZDB-ID	1195456-5
ISSN	1003-5370
ISSN	1003-5370
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2863: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: n-3 fatty acids and the prevention of coronary atherosclerosis.

von Schacky, C

The American journal of clinical nutrition

2000 Volume 71, Issue 1 Suppl, Page(s) 224S–7S

Abstract: ... of coronary atherosclerosis. However, in a recent study, occlusion of aortocoronary venous bypass grafts was reduced after 1 y ... that dietary n-3 fatty acids prevent restenosis after percutaneous coronary angioplasty or induce regression ... other sources of dietary n-3 fatty acids and cardiovascular events. Numerous mechanisms of action ...

Abstract	Epidemiologic studies have shown an inverse correlation between consumption of fish or other sources of dietary n-3 fatty acids and cardiovascular events. Numerous mechanisms of action for the favorable effect of dietary n-3 fatty acids on factors implicated in the pathogenesis of atherosclerosis have been described. Studies in dogs, swine, and nonhuman primates have consistently shown beneficial effects in various models of vasoocclusive diseases. Studies published currently do not indicate that dietary n-3 fatty acids prevent restenosis after percutaneous coronary angioplasty or induce regression of coronary atherosclerosis. However, in a recent study, occlusion of aortocoronary venous bypass grafts was reduced after 1 y by daily ingestion of 4 g fish-oil concentrate. In the Diet and Reinfarction Trial, 2-y overall mortality was reduced by 29% in survivors of a first myocardial infarction after consumption of n-3 fatty acid-rich fatty fish at least twice a week had been advised (Lancet 1989;2:757-61). When n-3 fatty acids were integrated into a diet resembling a traditional Mediterranean diet, 5-y cardiovascular mortality after a first myocardial infarction was reduced by 70% (Lancet 1994; 343:1454-9). Preliminary studies indicate that cardiac transplant patients could be an interesting focus of investigation. Currently, food sources rich in n-3 fatty acids are thought to be beneficial in secondary prophylaxis after a myocardial infarction. Large-scale clinical studies with endpoints such as morbidity and mortality are needed to more precisely define the role of n-3 fatty acids in primary and secondary prophylaxis of coronary atherosclerosis.
MeSH term(s)	Coronary Angiography/adverse effects ; Coronary Artery Disease/prevention & control ; Coronary Artery Disease/therapy ; Fatty Acids, Omega-3/administration & dosage ; Fatty Acids, Omega-3/pharmacology ; Fish Oils/administration & dosage ; Graft Occlusion, Vascular/prevention & control ; Heart Transplantation/physiology ; Humans ; Myocardial Infarction/mortality
Chemical Substances	Fatty Acids, Omega-3 ; Fish Oils
Language	English
Publishing date	2000-01
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	280048-2
ISSN	1938-3207 ; 0002-9165
ISSN (online)	1938-3207
ISSN	0002-9165
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Ue I Zs.208: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article: Antithrombotic therapy in the coronary vein graft patient.

Israel, D H / Adams, P C / Stein, B / Chesebro, J H / Fuster, V

Clinical cardiology

1991 Volume 14, Issue 4, Page(s) 283–295

Abstract: ... of saphenous vein graft disease early and late after operation. The pathogenesis of early vein graft occlusion is ... anticoagulants in the prevention of saphenous vein graft occlusion following coronary artery bypass grafting. ... hyperplasia or vein graft atherosclerosis. We describe the role of various platelet inhibitors and ...

Abstract	Coronary artery bypass grafting is an important therapeutic modality in the treatment of the patient with coronary artery disease; however, long-term results are limited by the development of saphenous vein graft disease early and late after operation. The pathogenesis of early vein graft occlusion is primarily thrombotic, while that occurring later frequently involves thrombosis superimposed on intimal hyperplasia or vein graft atherosclerosis. We describe the role of various platelet inhibitors and anticoagulants in the prevention of saphenous vein graft occlusion following coronary artery bypass grafting.
MeSH term(s)	Coronary Artery Bypass ; Fibrinolytic Agents/pharmacology ; Fibrinolytic Agents/therapeutic use ; Graft Occlusion, Vascular/physiopathology ; Graft Occlusion, Vascular/prevention & control ; Humans ; Saphenous Vein/transplantation ; Thrombolytic Therapy
Chemical Substances	Fibrinolytic Agents
Language	English
Publishing date	1991-04
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	391935-3
ISSN	1932-8737 ; 0160-9289
ISSN (online)	1932-8737
ISSN	0160-9289
DOI	10.1002/clc.4960140403
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1423: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito